Cutler Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Cutler Group’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$4K	–	5333
2022 Q2	$4K	Hold	300	–	–	﹤0.01%	3888
2022 Q1	$3K	Hold	300	–	–	﹤0.01%	4500
2021 Q4	$1K	Buy	+300	New	+$6.27K	﹤0.01%	5086
2017 Q3	–	Sell	-3,000	Closed	-$3K	–	6467
2017 Q2	$3K	Hold	3,000	–	–	﹤0.01%	5281
2017 Q1	$7K	Buy	+3,000	New	+$18.7K	﹤0.01%	4415
2016 Q2	–	Sell	-2,700	Closed	-$4K	–	7106
2016 Q1	$4K	Buy	+2,700	New	+$18.1K	﹤0.01%	5070

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group's ORMP Position: Q1 2023 in Review

Cutler Group sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 1,713 shares — an estimated $20K sold.

Cutler Group first reported a position in ORMP in Q4 2015 and held it in 11 quarters. The position peaked at $130K in Q1 2016. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

Cutler Group reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 1,713 Oramed Pharmaceuticals shares in Q1 2023, an estimated $20K.
Cutler Group first reported a position in Oramed Pharmaceuticals in Q4 2015 and held it in 11 quarters.
Cutler Group's Oramed Pharmaceuticals position peaked at $130K in Q1 2016.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.